Strides to Take Control of Bafna's India Branded Generics Buisness
Drug firm Strides Arcolab will acquire a majority stake in the India-branded generics business of Bafna Pharmaceuticals for a cash consideration of Rs 48.1 crore.
The two companies have signed an agreement for the acquisition, under which the India branded generics business of Bafna will be transferred to a special purpose vehicle (SPV) in which Strides will hold a 74 per cent stake while the remaining 26 per cent will be held by Bafna.
"The IPs and the manpower will be transferred to the SPV as part of the business transfer and Bafna will continue to manufacture these products for the SPV," Strides Arcolab said in a filing to the BSE.
The transaction is expected to close by September 2014, it added.
"This acquisition provides necessary impetus to our domestic branded generics business and the transaction is in line with our strategy to grow the company's branded generics business," Strides Arcolab founder and group CEO Arun Kumar said.
The transaction will strengthen Strides Arcolab's reach to newer markets with a wider portfolio of products, he added.
Pursuant to the transaction, Bafna will transfer entire India branded generics business as a going concern on a slump sale basis to Strides and will receive a cash consideration of Rs 48.1 crore and 26 per cent equity in the SPV, Bafna Pharmaceuticals said in a separate filing to the bourse.
Bafna Pharmaceuticals CMD Mahaveer Bafna said the transaction would help Bafna "de-leverage its balance-sheet and demonstrates our commitment to maximising value to our shareholders".
Under the proposed transaction, Bafna will continue to manufacture and supply the products from its existing manufacturing facilities for a period of five years, the filing noted.
India branded generics business of Bafna is engaged in sales and marketing of branded pharmaceutical products in niche therapeutic segments of haematinic, women healthcare, pediatric care in India and includes its flagship product 'Raricap' and 7 other brands.
The business has presence in 17 states in India with a field force of about 400 people and had revenue of Rs 24.6 crore for the financial year ended March 31, 2014.
Shares in Strides, on Monday, ended at Rs 668.95 apiece on the BSE, up 2.25 per cent from the previous close. Bafna shares, however, ended 4.99 per cent lower at Rs 34.25 apiece.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
